Education
About Us
Working with TipRanks
Follow Us
Geron Corporation (GERN)
:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $5.34
Previous CloseN/A
Volume1.63M
Average Volume (3M)11.67M
Market Cap
$808.89M
Enterprise Value$794.26M
Total Cash (Recent Filing)$406.57M
Total Debt (Recent Filing)$121.72M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 07, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding636,917,800
10 Day Avg. Volume12,785,109
30 Day Avg. Volume11,668,880
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.43
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue7.33
Enterprise Value/Gross Profit10.53
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$3.69Price Target Upside190.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Geron News
PremiumCompany Announcements
Geron Corporation’s Q1 2025 Financial HighlightsPremiumCompany Announcements
Geron Corporation’s Earnings Call: Mixed Sentiments and Strategic Moves
---
Bulls Say, Bears Say
Bulls Say
Growth StrategiesManagement provided details on launch strategies to drive new patient starts, including a 20% expansion to the field force.
Market DemandManagement is hopeful it will deliver based on early signs of progress including a ~10% demand increase from March - April.
Product ProfileRytelo has a decent product profile in a proven commercial market and can achieve meaningful sales growth over time.
Bears Say
Inventory IssuesThe surprise quarter-on-quarter decline on inventory shifts is an optical negative.
Revenue PerformanceRytelo net product revenues were below consensus and down due to inventory dynamics against flat demand.
Sales ExpectationsGeron reported Q1 Rytelo net sales of $39MM (-17% Q/Q), which is below our estimate of $49MM and consensus of $48MM.
---
Ownership Overview
0.07% Insiders
11.85% Mutual Funds
35.03% Other Institutional Investors
38.49% Public Companies and
Individual Investors
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.17 and its highest was $5.34 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $808.89M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 07, 2025 which is in 80 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 07, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.036 by $0.006.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corporation dividends here
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is -0.03.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 636,917,800 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.036. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
---
Geron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.69 (190.55% Upside)
$3.69 (190.55% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $221.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.43%
12-Months-Change
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
---
GERN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed sentiment. While there are encouraging signs of growth and strategic investments to bolster RYTELO's market presence, the decline in Q1 revenues, challenges in physician adoption, and reliance on third-party support in the EU present significant concerns. The ongoing executive transition adds to the uncertainty.Read More>---
GERN Stock 12 Month Forecast
Average Price Target
$3.69
▲(190.55% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Viridian Therapeutics
―
Spyre Therapeutics
―
Pulse Biosciences
―
Enliven Therapeutics
―
---